Feed additive manufacturer Chr Hansen has acquired a US microbial platform in a move it says will strengthen its probiotic production flexibility.
The Danish multinational has bought Wisconsin-based UAS Laboratories from private equity fund Lakeview Equity Partners for $530 million. The company, with 230 employees, is expected to generate additional revenues of around $85m and earnings of $30m before synergies in 2020.
UAS has two GMP facilities in Wisconsin, close to Chr. Hansen’s own facilities in Milwaukee. Its fermentation capacity and downstream processing will complement Chr Hansen’s existing facilities. It owns six trademarked probiotic strains within a range of indications including digestive disorders, immune stimulation, infant probiotics and weight management.
Hansen says the addition will be a strong fit with significant potentials for production, innovation and commercial synergies, primarily within human health but also its other markets.
“The acquisition of UAS Labs and its talented people enables us to join forces in our shared purpose to develop and expand the global probiotics market, and we look forward to building upon the strengths of both companies,” says Mauricio Graber, chief executive of Chr Hansen.